[Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level]
| Autor: | G, Mercadal Orfila, I, Blasco Mascaró |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Aged
80 and over Chronic Kidney Disease-Mineral and Bone Disorder Male Gastrointestinal Diseases Calcimimetic Agents Middle Aged Naphthalenes Parathyroid Hormone Renal Dialysis Practice Guidelines as Topic Humans Kidney Failure Chronic Female Hyperparathyroidism Secondary Cinacalcet Drug Monitoring Aged Retrospective Studies |
| Zdroj: | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 36(1) |
| ISSN: | 2171-8695 |
| Popis: | Cinacalcet is a calcimimetic agent, recommended for treating refractory secondary hyperparathyroidism in patients undergoing dialysis. The aim of this study was to evaluate the efficacy and safety of cinacalcet, comparing patients with baseline iPTH300 pg/ml with those with iPTH300 pg/ml.Observational retrospective study of patients being treated with cinacalcet 30 mg/day from January 2008 to January 2009. We studied 26 patients, 15 with iPTH300 pg/ml and 11 with iPTH300 pg/ml. The primary efficacy outcome was that there was a reduction between baseline and final iPTH (4 month). The secondary efficacy outcome were the reduction between basal and final calcium, phosphorus, Ca x P, and the percentage of patients with an iPTH decrease30%. The safety was evaluated based on the most frequent adverse effects and the levels of serum calcium8.6 mg/dl.Patients with initial iPTH300 had significant differences before and after cinacalcet treatment in iPTH (563.49+286.88 pg/ml vs 315.15+201.948 pg/ml; P=.017) and serum calcium (9.1+1.77 mg/dl vs 8.15+1.2mg/dl; P=.02). There were no significant differences in patients with initial iPTH300 pg/ml. A decrease greater than 30% from baseline iPTH was observed in 60% of patients with baseline iPTH300 pg/ml, and only in 27.3% of those with basal iPTH300 pg/ml (P=.098). Patients did not show gastric intolerance.Cinacalcet is an effective and safe drug for controlling secondary hyperparathyroidism in dialysis, mainly when it is used in patients with baseline iPTH300 pg/ml. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|